Hanmi’s 'Amoprel' Makes Global Waves: World’s First Ultra-Low Triple Hypertension Drug Lands in JACC
The Phase 3 clinical trial results for Hanmi Pharmaceutical’s Amoprel—the world’s first ultra-low-dose triple antihypertensive drug—were published on...